S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Biden signs bill extending a key US surveillance program after divisions nearly forced it to lapse
MarketBeat Week in Review – 4/15 - 4/19
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
Record Store Day celebrates indie retail music sellers as they ride vinyl's popularity wave
Panama Papers trial's public portion comes to an unexpectedly speedy end
NYSE:DNA

Ginkgo Bioworks (DNA) Stock Price, News & Analysis

$0.86
-0.06 (-6.49%)
(As of 04/19/2024 ET)
Today's Range
$0.85
$0.94
50-Day Range
$0.86
$1.55
52-Week Range
$0.85
$2.55
Volume
38.94 million shs
Average Volume
22.24 million shs
Market Capitalization
$1.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.20

Ginkgo Bioworks MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
154.4% Upside
$2.20 Price Target
Short Interest
Bearish
20.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of Ginkgo Bioworks in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$101,606 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.32) to ($0.28) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.27 out of 5 stars

Medical Sector

735th out of 911 stocks

Biological Products, Except Diagnostic Industry

125th out of 152 stocks

DNA stock logo

About Ginkgo Bioworks Stock (NYSE:DNA)

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

DNA Stock Price History

DNA Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Modalis Announces Partnership with Ginkgo Bioworks
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
See More Headlines
Receive DNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/20/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Fax
N/A
Employees
1,218
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.20
High Stock Price Target
$3.00
Low Stock Price Target
$1.10
Potential Upside/Downside
+157.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
5 Analysts

Profitability

Net Income
$-892,870,000.00
Net Margins
-355.08%
Pretax Margin
-355.11%

Debt

Sales & Book Value

Annual Sales
$251.46 million
Book Value
$0.55 per share

Miscellaneous

Outstanding Shares
2,152,400,000
Free Float
1,828,460,000
Market Cap
$1.84 billion
Optionable
Optionable
Beta
1.35
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

DNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Ginkgo Bioworks stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ginkgo Bioworks in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DNA, but not buy additional shares or sell existing shares.
View DNA analyst ratings
or view top-rated stocks.

What is Ginkgo Bioworks' stock price target for 2024?

5 Wall Street analysts have issued 1 year target prices for Ginkgo Bioworks' stock. Their DNA share price targets range from $1.10 to $3.00. On average, they expect the company's share price to reach $2.20 in the next year. This suggests a possible upside of 154.4% from the stock's current price.
View analysts price targets for DNA
or view top-rated stocks among Wall Street analysts.

How have DNA shares performed in 2024?

Ginkgo Bioworks' stock was trading at $1.69 on January 1st, 2024. Since then, DNA stock has decreased by 48.8% and is now trading at $0.8649.
View the best growth stocks for 2024 here
.

When is Ginkgo Bioworks' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our DNA earnings forecast
.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its earnings results on Thursday, February, 29th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.01. The business earned $34.76 million during the quarter, compared to the consensus estimate of $40.37 million. Ginkgo Bioworks had a negative net margin of 355.08% and a negative trailing twelve-month return on equity of 48.23%. The firm's revenue was down 64.6% on a year-over-year basis. During the same period last year, the business earned ($0.04) EPS.

What guidance has Ginkgo Bioworks issued on next quarter's earnings?

Ginkgo Bioworks updated its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $215.0 million-$235.0 million, compared to the consensus revenue estimate of $279.6 million.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (2.60%), Salem Investment Counselors Inc. (0.22%), Green Alpha Advisors LLC (0.01%), Quattro Financial Advisors LLC (0.01%) and First Trust Direct Indexing L.P. (0.00%). Insiders that own company stock include Barry Canton, Christian O Henry, Jason R Kelly, Marie E Fallon, Marijn E Dekkers, Mark E Dmytruk, Reshma P Shetty and Shyam Sankar.
View institutional ownership trends
.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:DNA) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners